The Top Analysis for CRISPR Therapeutics AG (CRSP)


The top analysis was written by AiAnalysis1 on YouTube titled CRISPR Therapeutics: A Turning Point for the Gene Editing Pioneer

Is CRISPR Therapeutics AG (CRSP) a buy?

Based on 2 suggestions, CRISPR Therapeutics AG(CRSP) is recommended as a BUY

Are These Ratings Good?

Based on 2 ratings, the average Return is -19.29%.
The community has not been successfully rating this stock.

Forecast for CRISPR Therapeutics AG (CRSP)

Based on the most recent price of $53.02,
the two year forecast for CRSP is $58.06.
The four year forecast is $63.09
Forecast is based on the aggregate sentiment of users on the platform. The sentiment of top investors get a higher ranking when assessing the forecast.